GSK3B and breast carcinoma: GSK3β acts as a mediator of rapamycin-induced growth inhibition: rapamycin treatment increases the activity of GSK3β and downregulates cyclin D1 levels in a GSK3β-dependent fashion in human breast cancer cell lines [12].